TY - JOUR
T1 - Promoting HIV indicator condition-guided testing in hospital settings (PROTEST 2.0): study protocol for a multicentre interventional study
AU - Bogers, Saskia J.
AU - Schim van der Loeff, Maarten F.
AU - Davidovich, Udi
AU - Boyd, Anders
AU - van der Valk, Marc
AU - Brinkman, Kees
AU - de Bree, Godelieve J.
AU - Reiss, Peter
AU - van Bergen, Jan E. A. M.
AU - Geerlings, Suzanne E.
AU - on behalf of the HIV Transmission Elimination AMsterdam (H-TEAM) Consortium
AU - van Bergen, J. E. A. M.
AU - Brokx, P.
AU - Deug, F.
AU - Heidenrijk, M.
AU - Prins, M.
AU - Reiss, P.
AU - van der Valk, M.
AU - de Bree, G. J.
AU - Brokx, P.
AU - Geerlings, S. E.
AU - Hoornenborg, E.
AU - Achterbergh, R. C. A.
AU - van de Beek, D.
AU - Brinkman, N.
AU - de Bruin, M.
AU - Bruisten, S.
AU - Coyer, L.
AU - Dijkstra, M.
AU - Geijtenbeek, T. B. H.
AU - Godfried, M. H.
AU - Goorhuis, A.
AU - Hankins, C. A.
AU - Hogewoning, A.
AU - Hovius, J. W.
AU - de Jong, K.
AU - Kootstra, N. A.
AU - Lauw, F.
AU - van der Meer, J. T.
AU - Mulder, B. J.
AU - Nellen, F. J.
AU - Peters, E.
AU - van der Poll, T.
AU - van Rooijen, M. S.
AU - Sonder, G. J.
AU - de Vries, H. J.
AU - van Vugt, M.
AU - Wiersinga, W. J.
AU - Wit, F. W.
AU - Zantkuijl, P.
AU - HIV Transmission Elimination AMsterdam (H-TEAM) Consortium
N1 - Funding Information: PROTest 2.0 is funded by Aids Fonds (grant number: P- 42702) and the H-TEAM. The H-TEAM initiative is supported by Aids Fonds (grant number: 2013169), Stichting Amsterdam Dinner Foundation, Bristol-Myers Squibb International Corp. (study number: AI424–541), Gilead Sciences Europe Ltd. (grant number: PA-HIV-PREP-16-0024), Gilead Sciences (protocol numbers: CO-NL-276-4222, CO-US-276-1712), Janssen Pharmaceutica (reference number: PHNL/JAN/0714/0005b/1912fde), M.A.C AIDS Fund, ViiV Healthcare (PO numbers: 3000268822, 3000747780) and ZonMw (grant number: 522002003). The funders of this study did not play any role in the design of the study and collection, analysis, and interpretation of data or in the writing of this manuscript or the decision to publish. Publisher Copyright: © 2021, The Author(s). Copyright: Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2021/12/1
Y1 - 2021/12/1
N2 - Background: Late presentation remains a key barrier towards controlling the HIV epidemic. Indicator conditions (ICs) are those that are AIDS-defining, associated with a prevalence of undiagnosed HIV > 0.1%, or whose clinical management would be impeded if an HIV infection were undiagnosed. IC-guided HIV testing is an effective strategy in identifying undiagnosed HIV, but opportunities for earlier HIV diagnosis through IC-guided testing are being missed. We present a protocol for an interventional study to improve awareness of IC-guided testing and increase HIV testing in patients presenting with ICs in a hospital setting. Methods: We designed a multicentre interventional study to be implemented at five hospitals in the region of Amsterdam, the Netherlands. Seven ICs were selected for which HIV test ratios (proportion of patients with an IC tested for HIV) will be measured: tuberculosis, cervical/vulvar cancer or high-grade cervical/vulvar dysplasia, malignant lymphoma, hepatitis B and C, and peripheral neuropathy. Prior to the intervention, a baseline assessment of HIV test ratios across ICs will be performed in eligible patients (IC diagnosed January 2015 through May 2020, ≥18 years, not known HIV positive) and an assessment of barriers and facilitators for HIV testing amongst relevant specialties will be conducted using qualitative (interviews) and quantitative methods (questionnaires). The intervention phase will consist of an educational intervention, including presentation of baseline results as competitive graphical audit and feedback combined with discussion on implementation and opportunities for improvement. The effect of the intervention will be assessed by comparing HIV test ratios of the pre-intervention and post-intervention periods. The primary endpoint is the HIV test ratio within ±3 months of IC diagnosis. Secondary endpoints are the HIV test ratio within ±6 months of diagnosis, ratio ever tested for HIV, HIV positivity percentage, proportion of late presenters and proportion with known HIV status prior to initiating treatment for their IC. Discussion: This protocol presents a strategy aimed at increasing awareness of the benefits of IC-guided testing and increasing HIV testing in patients presenting with ICs in hospital settings to identify undiagnosed HIV in Amsterdam, the Netherlands. Trial registration: Dutch trial registry: NL7521. Registered 14 February 2019.
AB - Background: Late presentation remains a key barrier towards controlling the HIV epidemic. Indicator conditions (ICs) are those that are AIDS-defining, associated with a prevalence of undiagnosed HIV > 0.1%, or whose clinical management would be impeded if an HIV infection were undiagnosed. IC-guided HIV testing is an effective strategy in identifying undiagnosed HIV, but opportunities for earlier HIV diagnosis through IC-guided testing are being missed. We present a protocol for an interventional study to improve awareness of IC-guided testing and increase HIV testing in patients presenting with ICs in a hospital setting. Methods: We designed a multicentre interventional study to be implemented at five hospitals in the region of Amsterdam, the Netherlands. Seven ICs were selected for which HIV test ratios (proportion of patients with an IC tested for HIV) will be measured: tuberculosis, cervical/vulvar cancer or high-grade cervical/vulvar dysplasia, malignant lymphoma, hepatitis B and C, and peripheral neuropathy. Prior to the intervention, a baseline assessment of HIV test ratios across ICs will be performed in eligible patients (IC diagnosed January 2015 through May 2020, ≥18 years, not known HIV positive) and an assessment of barriers and facilitators for HIV testing amongst relevant specialties will be conducted using qualitative (interviews) and quantitative methods (questionnaires). The intervention phase will consist of an educational intervention, including presentation of baseline results as competitive graphical audit and feedback combined with discussion on implementation and opportunities for improvement. The effect of the intervention will be assessed by comparing HIV test ratios of the pre-intervention and post-intervention periods. The primary endpoint is the HIV test ratio within ±3 months of IC diagnosis. Secondary endpoints are the HIV test ratio within ±6 months of diagnosis, ratio ever tested for HIV, HIV positivity percentage, proportion of late presenters and proportion with known HIV status prior to initiating treatment for their IC. Discussion: This protocol presents a strategy aimed at increasing awareness of the benefits of IC-guided testing and increasing HIV testing in patients presenting with ICs in hospital settings to identify undiagnosed HIV in Amsterdam, the Netherlands. Trial registration: Dutch trial registry: NL7521. Registered 14 February 2019.
KW - HIV Infections/diagnosis
KW - HIV testing
KW - Healthcare quality improvement
KW - Hospitals
KW - Humans
KW - Implementation
KW - Indicator condition
KW - Mass Screening/methods
KW - Multifaceted intervention
KW - Netherlands/epidemiology
KW - Patient Selection
KW - Prevalence
UR - http://www.scopus.com/inward/record.url?scp=85107207430&partnerID=8YFLogxK
UR - https://pure.uva.nl/ws/files/113956075/12879_2021_6183_MOESM1_ESM.docx
UR - https://pure.uva.nl/ws/files/113956077/12879_2021_6183_MOESM2_ESM.docx
U2 - https://doi.org/10.1186/s12879-021-06183-8
DO - https://doi.org/10.1186/s12879-021-06183-8
M3 - Article
C2 - 34078315
VL - 21
JO - BMC infectious diseases
JF - BMC infectious diseases
SN - 1471-2334
IS - 1
M1 - 519
ER -